Safety and efficacy findings from the open-label, multicenter, phase 3b, expanded treatment protocol study of ruxolitinib for treatment of patients with polycythemia vera who are resistant/intolerant to hydroxyurea and for whom no alternative treatments are available

Lynda M Foltz,Gianmatteo Pica,Hacene Zerazhi,Jan Van Droogenbroeck,Sorin Visanica,Enrique Báez-de la Fuente,Brian Leber,Antonio Almeida,Dana Ranta,Jean-Jacques Kiladjian,Linda Chrit,Albert Kandra,Juliane Morando,Timothy Devos

Safety and efficacy findings from the open-label, multicenter, phase 3b, expanded treatment protocol study of ruxolitinib for treatment of patients with polycythemia vera who are resistant/intolerant to hydroxyurea and for whom no alternative treatments are available

2019

Lynda M Foltz
Gianmatteo Pica
Hacene Zerazhi
Jan Van Droogenbroeck
Sorin Visanica
Enrique Báez-de la Fuente
Brian Leber
Antonio Almeida
Dana Ranta
Jean-Jacques Kiladjian
Linda Chrit
Albert Kandra
Juliane Morando
Timothy Devos

AbstractRuxolitinib was recently approved for the treatment of patients with polycythemia vera who are resistant/intolerant to hydroxyurea based on data from the RESPONSE studies. This phase 3b, Ex...

Keywords:

Immunology
Diabetes mellitus
Ruxolitinib
Polycythemia vera
Internal medicine
Medicine
treatment protocol
open label

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations